Alzheimer's disease neprilysin gene therapy

Drug Profile

Alzheimer's disease neprilysin gene therapy

Alternative Names: Alzheimer's disease gene therapy; Lenti-Nep

Latest Information Update: 11 Dec 2007

Price : $50

At a glance

  • Originator Salk Institute; University of California, San Diego; University of Kentucky
  • Class Antidementias; Gene therapies; Neuroprotectants
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 11 Dec 2007 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
  • 25 Aug 2006 No development reported - Preclinical for Alzheimer's disease in USA (unspecified route)
  • 28 Jul 2003 A preclinical study has been added to the Alzheimer's disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top